Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unleashing Power of Psychedelics

Rhea-AI Summary

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) has been featured in an editorial by NetworkNewsWire, titled "Psychedelic Therapies Offer Hope for Mental Health." The editorial emphasizes the urgent need for effective treatments for mental health disorders, affecting nearly 1 in 8 people globally. Cybin is actively researching and forming partnerships to develop psychedelic-based therapies aimed at addressing a range of mental health issues. Founded in 2019, the company is dedicated to advancing innovative drug delivery systems and therapeutic regimens.

Positive

• Cybin is pioneering research in psychedelic therapeutics, addressing significant gaps in mental health treatment.
• The company has formed important partnerships to advance its research and development efforts.
• There is growing recognition of the need for effective treatments for mental health disorders, aligning with Cybin's focus.

Negative

• None.

NEW YORK, March 03, 2022 (GLOBE NEWSWIRE) -- via InvestorWire — Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 50+ trusted brands within the InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities.

To view the full publication, “Psychedelic Therapies Offer Hope for Mental Health,” please visit: https://nnw.fm/JeGwq

Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of the nervous system to change its activity in response to stimuli often produces stress-induced neuroplasticity, which plays a critical role in almost all mental disorders. The problem is conventional drugs have done little to correct damage in this response, resulting in mental health disorders that now affect nearly one in every eight people on the planet.

Amazingly, research with psychedelic therapeutics has shown great promise, inspiring hope in treating a broad range of mental health disorders. With the urgent need for new, more effective treatments to treat a wide spectrum of disorders, Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) is pioneering groundbreaking research and striking important partnerships to unleash the power of these psychedelic-based compounds.

About Cybin Inc.

Cybin is a leading ethical biopharmaceutical company working with a network of world-class partners and internationally recognized scientists on a mission to create safe and effective therapeutics for patients to address a multitude of mental health issues. Headquartered in Canada and founded in 2019, Cybin is operational in Canada, the United States, United Kingdom and Ireland. The company is focused on progressing Psychedelics to Therapeutics(TM) by engineering proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for mental health disorders.

For more information, visit the company’s website at www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://nnw.fm/CYBN

About NetworkNewsWire

NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness.

NNW is where news, content and information converge.

To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

NetworkNewsWire is part of the InvestorBrandNetwork

FAQ

What is Cybin Inc.'s recent press release about?

Cybin Inc. has been featured in an editorial discussing the potential of psychedelic therapies for mental health issues.

What are the key highlights from Cybin's editorial in NetworkNewsWire?

The editorial highlights the urgent need for effective mental health treatments and Cybin's commitment to research in psychedelic therapeutics.

How does Cybin Inc. plan to tackle mental health disorders?

Cybin aims to develop psychedelic-based therapies through innovative drug delivery systems and partnerships with top scientists.

What is the significance of psychedelic therapies according to Cybin's press release?

Psychedelic therapies are presented as a promising approach to addressing the limitations of conventional mental health treatments.

When was Cybin Inc. founded?

Cybin Inc. was founded in 2019.